Anebulo Pharmaceuticals, Inc. Quarterly Debt-to-equity in % from Q4 2021 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Anebulo Pharmaceuticals, Inc. quarterly Debt-to-equity history and growth rate from Q4 2021 to Q3 2024.
  • Anebulo Pharmaceuticals, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 16.6 %, a 69.3% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 16.6 +6.8 +69.3% Sep 30, 2024
Q2 2024 12.7 +4.75 +59.7% Jun 30, 2024
Q1 2024 12.5 +6.02 +92.6% Mar 31, 2024
Q4 2023 11.2 +7.19 +180% Dec 31, 2023
Q3 2023 9.81 +7.89 +412% Sep 30, 2023
Q2 2023 7.96 +6.19 +350% Jun 30, 2023
Q1 2023 6.5 +5.23 +411% Mar 31, 2023
Q4 2022 3.99 -19 -82.6% Dec 31, 2022
Q3 2022 1.92 Sep 30, 2022
Q2 2022 1.77 Jun 30, 2022
Q1 2022 1.27 Mar 31, 2022
Q4 2021 22.9 Dec 31, 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.